SCHEMBL4464531

SCHEMBL4464531

CCS(=O)(=O)c1cccc(C(=O)NC2=NNC(=O)C2=C2C=Cc3ccccc3N2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.42
KDM4B O94953 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
POLB P06746 1/20 0.40
BLM P54132 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
LMNA P02545 4/20 0.38
TSHR P16473 3/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 3/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 2/20 0.35
APEX1 P27695 1/20 0.35
ALPL P05186 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464526 1.00 KDM4A (0.42) KDM4AKDM4BKDM5BPOLBBLM
SCHEMBL4462142 0.84 MAPT (0.37) GAASMN1; SMN2LMNAKMT2AMEN1
SCHEMBL4462878 0.77 MAPT (0.38) GAASMN1; SMN2LMNAKMT2AMEN1
SCHEMBL4462876 0.77 MAPT (0.38) GAASMN1; SMN2LMNAKMT2AMEN1
SCHEMBL4474579 0.77 BRD4 (0.38) GAAMAPT
SCHEMBL4474572 0.77 BRD4 (0.38) GAAMAPT
SCHEMBL4474662 0.75 SMN1; SMN2 (0.39) POLBGAASMN1; SMN2ALDH1A1MAPT
SCHEMBL4474657 0.75 SMN1; SMN2 (0.39) POLBGAASMN1; SMN2ALDH1A1MAPT
SCHEMBL4467054 0.72 SMN1; SMN2 (0.41) GAASMN1; SMN2LMNATSHRKMT2A
SCHEMBL4467058 0.72 SMN1; SMN2 (0.41) GAASMN1; SMN2LMNATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US claimed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP claimed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO claimed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US claimed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US disclosed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP disclosed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO disclosed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041137-A1 Kinase inhibitors MAP3K19, MAP3K20, MAP3K1 KDM4A 1161/4885KDM4B 966/4885KDM5B 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.